Dicerna Pharmaceuticals, Inc.

Marc Abrams

Martin Koser

Bob Dale Brown

Henryk T Dudek

Shanthi Ganesh

Anton Turanov

Wen Han

Jihye Park

Girish Chopda

Utsav Saxena

Oligonucleotides are provided herein that inhibit apolipoprotein(a) (LPA) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with LPA expression.

Compositions and methods for inhibiting LPA expression

Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with PNPLA3 expression.

Compositions and methods for modulating PNPLA3 expression

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a &#x3b2;-catenin inhibitor and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a &#x3b2;-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a &#x3b2;-catenin inhibitor, such as a &#x3b2;-catenin nucleic acid inhibitor molecule.

Reducing beta-catenin expression to potentiate immunotherapy

Disclosed herein are methods for the treatment of cancer, comprising administering to a subject &#x3b2;-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of &#x3b2;-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.

Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.

Compositions and methods for inhibiting HMGB1 expression

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

Methods for treating hepatitis B infection

Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a &#x3b2;-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a &#x3b2;-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.

Growing community of inventors

Lexington, MA, United States of America

Marc Abrams